Aditya Birla Sunlife Life Pharma & Healthcare Growth Direct Plan
SIP amount
Min. ₹100
Lumpsum amount
Min. ₹1,000

Aditya Birla Sunlife Life Pharma & Healthcare Growth Direct Plan

NAV
₹33.9600
+0.24%
(12 Dec)
AUM
854 Cr
TER
1.03%
Risk
Very High Risk
Insights
Net Asset Value (NAV) is above its 200 days moving average
Total Expense Ratio (TER) is in the top 25% of comparable funds
In beta. Send feedback here.
Compare with other fund
1Y
+14.7%
+5.2%
+1.7%
+1.0%
+0.9%
3Y
+29.7%
+28.4%
+29.1%
+28.2%
+22.3%
5Y
NA
+19.5%
+24.8%
+28.5%
+15.8%
ALL
+28.0%
+21.9%
+18.0%
+16.8%
+20.9%
VOL
14.4%
15.2%
16.2%
19.6%
15.3%
TER
1.0%
1.0%
0.5%
0.9%
1.0%
AUM
₹3,073 Cr
₹6,460 Cr
₹8,189 Cr
₹1,445 Cr
₹854 Cr
INFO
1.94
1.44
1.11
0.85
1.36
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
Aditya Birla Sunlife Life Pharma & Healthcare (G)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 30th Nov
Top holdings
Sun Pharmaceuticals Industries Ltd
12.5%
Apollo Hospitals Enterprise Ltd
7.3%
Cipla Ltd
6.8%
Lupin Ltd
4.8%
Abbott India Ltd
4.6%
Torrent Pharmaceuticals Ltd
4.5%
J.B. Chemicals & Pharmaceuticals Ltd
4.3%
Aurobindo Pharma Ltd
4.2%
Fortis Healthcare Ltd
4.1%
Ajanta Pharma Ltd
3.9%
Top industry exposure
Healthcare
96.8%
Basic Materials
0.9%
Other information
Minimum SIP
₹100
Minimum lumpsum
₹1,000
Additional lumpsum
₹1,000
Portfolio turnover
33%
Lock-in period
-
Exit load
• 1% for redemption within 30 days
Fund objective
The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. The Scheme does not guarantee/indicate any returns. There can be no assurance that the schemes’ objectives will be achieved.
Fund manager(s)
Dhaval Shah

FAQs